Therapeutic Response

HER2-positive status confers therapeutic sensitivity to Paclitaxel in combination with Pertuzumab and Trastuzumab in patients with Invasive Breast Carcinoma.

Statements

Source and description
Pertuzumab/Trastuzumab (Phesgo) and Weekly PACLitaxel Therapy - 21 day cycle. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab / trastuzumab (phesgo) in combination with paclitaxel for reimbursement as a treatment option for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease where patients are intolerant of, have had significant toxicity to, or are deemed clinically unsuitable for docetaxel.
Pertuzumab,Trastuzumab and Weekly PACLitaxel Therapy - 21 day cycle. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved pertuzumab in combination with trastuzumab and paclitaxel for reimbursement as a treatment option for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease where patients are intolerant of, have had significant toxicity to, or are deemed clinically unsuitable for docetaxel.